[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fZ49jNgYSWS-vbBlORDw1yMkWF-Es9rojWZ0eXtrzW94":8,"$f0cC6tL8za106psHO-SfgpqUbWS6LrGfTyTJsGEGp1N0":55,"$fvBbCJbXLVxuiCXvt3pQO_KilLoQQBgCCp87Kb7zV29U":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},56520,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"肺癌ALK阳性：最新治疗进展与用药指南 💊","","https://ystcdn.venuertc.com/venue/AI/38cc3a59-a1ef-4fcc-8e72-a0c48c276117.jpg","\u003Cdiv id=\"material_title\" class=\"alk-title\">\n    \u003Cspan>肺癌ALK阳性：最新治疗进展与用药指南 💊\u003C/span>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品知识概览：ALK阳性与靶向药物\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cp>\n            提到ALK靶向药物，很多人并不陌生，比如洛拉替尼、阿来替尼等。这类药品主要针对ALK基因重排的患者，能够干扰肿瘤细胞的特定信号通路。靶向治疗通常在特定人群中应用，因其精准性成为近年来关注的焦点。\n        \u003C/p>\n        \u003Cp>\n            今天我们将讲清楚6个关键环节：常见ALK靶向与辅助用药的成分、剂型，作用机制，用法用量，药物相互作用，主要不良反应，储存方法。了解这些细节，能让用药更安全、更有效。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 常见ALK阳性靶向药物成分与剂型 🌱\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\u003Cstrong>洛拉替尼（Lorlatinib）\u003C/strong>：口服片剂，规格通常为25 mg、100 mg。\u003C/li>\n            \u003Cli>\u003Cstrong>阿来替尼（Alectinib）\u003C/strong>：口服胶囊或片剂，常见规格为150 mg。\u003C/li>\n            \u003Cli>\u003Cstrong>克唑替尼（Crizotinib）\u003C/strong>：口服胶囊，通常规格为250 mg。\u003C/li>\n            \u003Cli>\u003Cstrong>培美曲塞（Pemetrexed）\u003C/strong>：注射剂型，按体表面积计算剂量。\u003C/li>\n            \u003Cli>\u003Cstrong>卡铂（Carboplatin）\u003C/strong>：静脉注射剂型，具体剂量根据用药方案和耐受性个体化选择。\u003C/li>\n            \u003Cli>\u003Cstrong>贝伐珠单抗（Bevacizumab）\u003C/strong>：静脉滴注剂型，多用于联合辅助。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            正确做法：仔细核对药品名称和剂型，严格按说明书或医嘱服用/注射，切勿自行更换或调整剂量。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 药物作用机制简介🧬\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>洛拉替尼/阿来替尼/克唑替尼：\u003C/strong>抑制ALK（间变性淋巴瘤激酶）信号通路，阻断肿瘤细胞生长和扩散。\u003Cbr>\n                临床研究显示，这些药物能有效控制ALK突变相关肿瘤细胞的分裂与增殖（Solomon, B.J., et al., 2014）。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>培美曲塞：\u003C/strong>属于叶酸代谢拮抗剂，阻断肿瘤细胞合成DNA的关键步骤，抑制细胞增殖。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>卡铂：\u003C/strong>通过与癌细胞DNA结合，导致DNA链断裂，使肿瘤细胞丧失复制能力。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>贝伐珠单抗：\u003C/strong>为抗血管生成药物，阻止肿瘤产生新血管，限制肿瘤营养供应。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            需要注意：这些药品专为相应分子靶点设计，非靶点人群使用无效，且可能增加副作用风险。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 服药时间与正确用法\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>洛拉替尼：\u003C/strong>每日一次，建议同一时间服用，餐前餐后均可。整片吞服，勿掰碎、嚼碎。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>阿来替尼：\u003C/strong>每日两次，建议随餐服用以提高吸收，胶囊整粒吞服。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>克唑替尼：\u003C/strong>每日两次，食品对其影响较小，推荐配水整粒吞服。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>培美曲塞、卡铂、贝伐珠单抗：\u003C/strong>均为静脉注射，须在医院由专业人员操作。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            正确做法：每次服药配半杯（100-200毫升）清水，避免用茶、饮料送服。如漏服，请尽快补服，但切勿一次服用双倍剂量。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 常规用量及调整方案\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>洛拉替尼：\u003C/strong>推荐初始剂量100 mg，每日1次。部分患者根据耐受性可调整剂量，最高不超过100 mg/天。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>阿来替尼：\u003C/strong>常用剂量为600 mg（150 mg 4粒），每日2次。剂量调整根据副作用表现，仅在医生指导下进行。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>克唑替尼：\u003C/strong>通常剂量250 mg，每日2次。肝、肾功能减退患者应遵医嘱调整剂量。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>培美曲塞：\u003C/strong>按体表面积计算，用于每3周一次静脉注射。需补充叶酸和维生素B12减少副作用。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>卡铂：\u003C/strong>剂量根据公式计算且个体化调整。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>贝伐珠单抗：\u003C/strong>常见剂量为每次7.5~15 mg/kg，2-3周一次，经静脉点滴。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            特别提醒：任何剂量调整须严格依赖医生判断，不可自作主张变更。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 药物相互作用和联合用药提示 ⚠️\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>洛拉替尼：\u003C/strong>与强效CYP3A抑制剂（如伊曲康唑）、CYP3A诱导剂（如利福平）、圣约翰草等合用会影响血药浓度，容易降低疗效或加大毒性风险。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>阿来替尼：\u003C/strong>与某些抗真菌药、抗癫痫药、HIV药物（强CYP3A4调节剂）合用需调整剂量。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>克唑替尼：\u003C/strong>避免与葡萄柚或其制品同用，以防药效变化。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>贝伐珠单抗：\u003C/strong>与抗凝药、降压药同用要小心出血及降压反应。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            正确做法：配合使用这些药品前，详细告知医生所有正在用的药，包括非处方和保健品。\u003Cbr>\n            \u003Cspan class=\"alk-case alk-warning\">\n                ⓘ 有位患者用洛拉替尼时同时服用了圣约翰草，导致药效明显下降，后调整为不合用后疗效恢复。\n            \u003C/span>\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 主要不良反应及处理方法\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>洛拉替尼：\u003C/strong>部分患者出现高胆固醇、认知异常、外周水肿等。认知障碍一般经过调整剂量可以缓解（FDA说明书，Pfizer, 2019）。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>阿来替尼：\u003C/strong>部分出现便秘、肌肉痛、肝酶升高、心率变化，通常为轻度。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>克唑替尼：\u003C/strong>常见不良反应为胃肠道反应（恶心、呕吐）、视觉异常、浮肿等。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>培美曲塞、卡铂：\u003C/strong>注射后有可能引发骨髓抑制（白细胞下降）、肾功能影响等，极少数出现过敏反应。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>贝伐珠单抗：\u003C/strong>部分患者发生高血压、蛋白尿、出血等。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            正确做法：应用过程中出现异常（如严重头痛、混乱、皮疹），立刻就医，不要自行停药。\u003Cbr>\n            \u003Cspan class=\"alk-case alk-light\">\n                ⓘ 临床上使用阿来替尼时，部分患者表现心率减慢，医生及时调整了剂量后症状缓解。\n            \u003C/span>\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 特殊人群用药注意事项 👴👵🧒🤰\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>老年人：\u003C/strong>应密切监测肝肾功能变化，必要时调整剂量。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>孕妇与哺乳期妇女：\u003C/strong>洛拉替尼、阿来替尼、贝伐珠单抗等禁用于怀孕、哺乳期；生育期女性用药期间应严格避孕。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>肝、肾功能障碍者：\u003C/strong>阿来替尼、克唑替尼在肝肾功能明显降低患者中要慎用，用药方案需经专家根据具体情况调整。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>儿童及青少年：\u003C/strong>目前多数ALK抑制剂未获得儿童使用批准，请勿随意应用。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            正确做法：特殊人群每次用药均须严格依赖医生具体指导，切不可根据成人剂量盲目用药。孕妇及哺乳期妇女禁止接触贝伐珠单抗及大部分ALK靶向药。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 储存与药品过期处理\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cul>\n            \u003Cli>\n                \u003Cstrong>洛拉替尼、阿来替尼、克唑替尼：\u003C/strong>室温（20-25℃）避光、干燥处保存，避免潮湿和高温环境。勿将药放在浴室等潮湿场所。\n            \u003C/li>\n            \u003Cli>\n                \u003Cstrong>培美曲塞、卡铂、贝伐珠单抗：\u003C/strong>为冷藏保存药物，2~8℃冷藏，避免冷冻。\n            \u003C/li>\n            \u003Cli>\n                开封后药品应标注日期，一旦超过有效期，切勿再服用。过期药品不随生活垃圾丢弃，应交回医院、药店或专业回收点。\n            \u003C/li>\n        \u003C/ul>\n        \u003Cp>\n            正确做法：定期自查药品，按批号和有效期先用先取，长期不用的药物及时处理。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 用药案例分享与实用经验\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Cdiv class=\"alk-case alk-light\">\n            一位67岁男性，长期规范服用洛拉替尼和辅助化疗药物，未出现严重不良反应，定期复查和密切沟通有效保证了安全用药。\n        \u003C/div>\n        \u003Cdiv class=\"alk-case alk-warning\">\n            临床中发现，有患者合用葡萄柚汁与克唑替尼，出现药效异常，停用葡萄柚汁后药物反应恢复正常。\n        \u003C/div>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">11 用药安全总结与关键信息回顾✨\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content\">\n        \u003Col>\n            \u003Cli>严格按照说明书和医生嘱咐选用剂型与剂量。\u003C/li>\n            \u003Cli>密切警惕药品相互作用，服药前主动说明所有药物和补品情况。\u003C/li>\n            \u003Cli>规范储存药品，防止受潮、高温导致变质。\u003C/li>\n            \u003Cli>出现不良反应或意外情况要及时就医，不要擅自处理。\u003C/li>\n            \u003Cli>特殊人群必须个性化用药评估，孕妇和哺乳期妇女杜绝自行用药。\u003C/li>\n        \u003C/ol>\n        \u003Cp>\n            正确服用ALK相关靶向与辅助药物，多一步细致的准备，少一次风险。未来药物研究在持续进步，建议大家密切关注新版指南。如有困惑，一定联系专业医生，不要随意停用或更换方案。\n        \u003C/p>\n    \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"alk-section\">\n    \u003Cdiv class=\"alk-subtitle-bg\">\n        \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"alk-content alk-ref\">\n        \u003Col>\n            \u003Cli>Solomon, B. J., Mok, T., Kim, D-W., Wu, Y-L., Nakagawa, K., Mekhail, T., ... & Shaw, A. T. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 371(23), 2167-2177.\u003C/li>\n            \u003Cli>Pfizer Inc. (2019). Lorlatinib [Prescribing Information]. U.S. Food and Drug Administration.\u003C/li>\n            \u003Cli>Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D-W., ... & Soria, J. C. (2017). Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 377(9), 829-838.\u003C/li>\n            \u003Cli>Reck, M., Mok, T., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., ... & Papadimitrakopoulou, V. A. (2019). Atezolizumab plus bevacizumab and chemotherapy in non–small-cell lung cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 380(24), 2246-2256.\u003C/li>\n            \u003Cli>National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2.2024.\u003C/li>\n        \u003C/ol>\n    \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立样式，避免影响嵌入页面布局 */\n.alk-title {\n    font-size: 2.2rem;\n    text-align: center;\n    font-weight: bold;\n    color: #31434c;\n    padding: 32px 0 12px 0;\n    letter-spacing: 2px;\n    background: linear-gradient(90deg, #e2f1fc 0%, #f0faf1 100%);\n    border-radius: 10px;\n    margin-bottom: 24px;\n}\n\n.alk-section {\n    margin-bottom: 32px;\n}\n\n.alk-subtitle-bg {\n    background: linear-gradient(90deg, #f7fafc 85%, #eaf6fb 100%);\n    padding: 18px 16px 16px 18px;\n    border-radius: 8px;\n    margin-bottom: 6px;\n    box-shadow: 0 2px 6px 0 rgba(79,130,204,0.03);\n}\n\n.alk-subtitle-bg h2 {\n    font-size: 1.35rem;\n    color: #22576c;\n    font-weight: 600;\n    margin: 0;\n    letter-spacing: 1px;\n    line-height: 1.6;\n    display: flex;\n    align-items: center;\n    gap: 8px;\n}\n\n.alk-content {\n    background: #fcfcfe;\n    padding: 18px 22px 14px 24px;\n    border-radius: 7px;\n    font-size: 1.08em;\n    color: #3a4652;\n    line-height: 2;\n    margin-bottom: 8px;\n    box-shadow: 0 2px 10px 0 rgba(39, 71, 130, 0.03);\n}\n\n.alk-content ul {\n    margin-left: 16px;\n    margin-bottom: 10px;\n    padding-left:20px;\n}\n\n.alk-content ol {\n    margin-left: 20px;\n    margin-bottom: 10px;\n    padding-left:22px;\n}\n\n.alk-content li {\n    margin-bottom: 8px;\n    font-size: 1em;\n}\n\n.alk-case {\n    display: block;\n    margin: 12px 0;\n    padding: 11px 18px;\n    border-radius: 8px;\n    font-size: 1em;\n    line-height: 1.8;\n    font-style: italic;\n    background: #f3f8fd;\n    box-shadow: 0 1px 4px 0 rgba(98,175,238,0.05);\n    border-left: 5px solid #a4d8fa;\n}\n\n.alk-light {\n    background: #f5faf7;\n    border-left: 5px solid #85dab1;\n    color: #203f36;\n}\n\n.alk-warning {\n    background: #fff9ed;\n    border-left: 5px solid #fec36a;\n    color: #5c4817;\n}\n\n.alk-ref {\n    font-size: 0.98em;\n    color: #557;\n    background: #f9fbfe;\n}\n\n@media (max-width: 700px) {\n    .alk-title { font-size:1.1rem; padding:18px 0 6px }\n    .alk-content, .alk-subtitle-bg { padding:12px;}\n}\n\u003C/style>\n\n","\u003Cdiv id=\"material_title\" class=\"alk-title\">\n    \u003Cspan>肺癌ALK阳性：最新治疗进展与用药指南 💊\u003C/span>\n\u003C/div>\n\n\u003Cdiv cla",417,"2025-08-07 11:16:13","肺癌, ALK阳性, 靶向药物, 药物治疗, 用药指南, 肺癌治疗, ALK抑制剂, 用药安全, 肺癌患者, 治疗方案","了解ALK阳性肺癌的新药物治疗进展及用药指南，为患者提供科学、权威的用药信息。获取安全用药、疗效提升和疾病管理的重要建议，助您在抗癌路上稳步前行。","2025-08-08 09:22:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]